Category: ACN Newswire

- The HKTDC returns with the second Hong Kong Shopping Festival in August, building on the initiatives in the 2024 Policy Address to help local SMEs expand into the Mainland China market through e-commerce channels- The Hong Kong Shopping Festival is the flagship event of the E-commerce Express, and has received an enthusiastic response, attracting nearly 260 brands presented by Hong Kong SMEs across seven major categories, providing them with practical opportunities to operate on key e-commerce platforms in the mainland- Fully supported by the Hong Kong Special Administrative Region (HKSAR) Government, Financial Secretary of the HKSAR Government Paul Chan filmed a promotional video for the Hong Kong Shopping Festival.HONG KONG, July 30, 2025 - (ACN Newswire via SeaPRwire.com) - The second Hong Kong Shopping Festival, organised by the Hong Kong Trade Development Council (HKTDC) will take place on Mainland e-commerce platforms from 1 to 31 August. Fully aligned with measures outlined in the 2024 Policy Address, the festival aims to support Hong Kong's small and medium-sized enterprises (SMEs) as they expand into the Mainland e-commerce market. As the flagship event of HKTDC's E-commerce Express, the Hong Kong Shopping Festival has attracted nearly 260 brands across seven major categories, including health supplements, food and beverages, home and living, personal care and cosmetics, apparel and accessories, smart gadgets, and products for the silver market. The festival features over 500 unique products and offers month-long discount promotions. With the full support of the Government of the Hong Kong Special Administrative Region (HKSAR), a launch ceremony for the second Hong Kong Shopping Festival was held today. The Financial Secretary of the HKSAR Government Paul Chan also filmed a promotional video for the campaign (video link: https://bit.ly/4mkvpec). Algernon Yau, Secretary for Commerce and Economic Development of the HKSAR Government said: “Building on the great success of the first edition of the Hong Kong Shopping Festival last year, this year’s event has attracted even more brands to participate. E-commerce is a major global trend in retail development. In 2024, the cross-border e-commerce market of the Mainland with vast potential reached over RMB17 trillion, presenting a golden opportunity for Hong Kong businesses to expand. In light of this, the government has been fully supporting industry upgrading and transformation through various measures to help enterprises establish online sales channels. The Hong Kong Shopping Festival serves as an ideal platform to showcase the city's premium products to more Mainland consumers."Patrick Lau, Deputy Executive Director, HKTDC, said: “New consumer trends are emerging in the Mainland market, reshaping buying habits and creating tremendous opportunities for Hong Kong businesses. While Hong Kong SMEs offer high-quality products, they need to understand the local business environment and e-commerce practices to successfully enter this vast market. As the flagship event of HKTDC's E-commerce Express, the second Hong Kong Shopping Festival will partner with major e-commerce and social media platforms for promotion and include a series of training sessions focused on the Mainland e-commerce market. This initiative aims to help businesses effectively tap into opportunities in Mainland e-commerce and connect with their target customers.”In November 2024, the Hong Kong Trade Development Council (HKTDC) released a research study on the development of cross-border e-commerce for Hong Kong traders. HKTDC Director of Research, Irina Fan, said over 60% of surveyed Hong Kong businesses view the Mainland Chinese market as the most promising e-commerce market in the coming one to two years. To help Hong Kong businesses gain insights into the Mainland e-commerce market, HKTDC Research interviewed 2,200 Mainland consumers from different regions about their online shopping behavior and characteristics. Ms Fan said: “Mainland China is the world’s largest e-commerce market and has a well-developed e-commerce industry. Hong Kong businesses must gain a deep understanding of Mainland consumers’ online shopping behaviors, their preferences for Hong Kong products, and the factors they consider when choosing e-commerce platforms. Only then can they formulate appropriate business strategies and effectively capture opportunities in the Mainland e-commerce retail market.” The latest research report: Hong Kong Businesses Navigating Mainland China E-commerce Retail Market - Consumer Survey Results will be released on 7 August 2025.The Hong Kong Shopping Festival aims to help Hong Kong businesses take advantage of the large customer base and traffic on Mainland e-commerce platforms, boosting their brand and product visibility while providing practical opportunities. Last year's inaugural edition was very successful, with total views on e-commerce platforms, social media, and the event's official website exceeding 90 million. This year, the HKTDC has enhanced the programme, enabling businesses to better seize market opportunities and speed up their expansion into the Mainland market.To enhance support for Hong Kong SMEs and local brands entering the Mainland e-commerce market, this year's Hong Kong Shopping Festival has introduced thematic seminars and one-on-one consultancy services. From late 2024 to June 2025, HKTDC has successfully organised a series of training sessions led by marketing experts, who shared practical insights on topics such as cross-border e-commerce, logistics, payment tools, marketing skills, and live-stream production. Additionally, nearly 50 one-on-one consulting meetings were held, where Mainland marketing experts offered tailored e-commerce strategies to individual participating companies based on the unique characteristics of their products.This year, Discount Month and live-streaming e-commerce will return with enhanced offering. Discount Month will take place from 1 to 31 August, with all Hong Kong businesses involved in the Hong Kong Shopping Festival offering discounts of up to 75%. This initiative not only helps businesses grow but also allows consumers to buy high-quality products from Hong Kong online. The official website of Hong Kong Shopping Festival will provide event details, live-streaming schedules and information about participating brands, products and discounts. In addition, HKTDC will promote the campaign through online and offline platforms, including Xiaohongshu, Douyin, Taobao, JD and others, to boost visits to the official website and, redirect them to the SMEs’ online stores.HKTDC recently hosted the debut “Product Selection Showcase” which attracted over 40 popular KOLs and their teams from platforms like Taobao, JD.com, and Douyin to connect with participating brands offline in Hong Kong. They experienced the products firsthand, learned about the brand stories, shared highlights and live-stream previews. In early August, HKTDC’s invited Mainland key opinion leaders (KOLs), including Li Jiaqi, Lin Yilun and Hu Ke, will conduct 35 live-streaming sessions for more than 80 brands on major e-commerce platforms, in which nearly 20 live-streaming sessions will take place in Hong Kong for the first time, allowing Mainland consumers to fully experience shopping in Hong Kong. This arrangement will make live-streaming more appealing, enhance visibility for Hong Kong products and brands, and build consumer trust and interest, while providing a valuable live-streaming experience for participating businesses.Mainland online marketing strategies are diverse and multifaceted. Beyond live-streaming, there are numerous ways to enhance brand exposure. Ryan Tse, President of the Hong Kong Health Food Association, Director of Vita Green Health Products Co., Ltd., Elijandy, Founder and Director of Cross International Ltd and Jones Ng, Founder of Chiwa Digital Media Capital Group Ltd. shared valuable insights in e-commerce marketing and promotion at the launch ceremony. Artist Samantha Ko Hoi Ling talked about her experiences in live-streaming and online shopping, further enhancing the effectiveness and exposure of the second Hong Kong Shopping Festival.Hong Kong Shopping Festival: https://f1546.vrupup.com/s/1546/f/main.html#/Photo Download: http://bit.ly/3IS8gRVPatrick Lau, Deputy Executive Director, HKTDC (third from right); Ryan Tse, President of the Hong Kong Health Food Association, Director of Vita Green Health Products Co., Ltd. (second from right); Elijandy, Founder and Director of Cross International Ltd. (first from left); Jones Ng, Founder of Chiwa Digital Media Capital Group Ltd. (first from right) and Samantha Ko Hoi Ling, Artist (second from left), attend the launch ceremony for the second Hong Kong Shopping Festival.The Hong Kong Special Administrative Region (HKSAR) Government provides full support to the Hong Kong Shopping Festival. Paul Chan, Financial Secretary of the HKSAR Government, filmed a promotional video.Patrick Lau, Deputy Executive Director of HKTDC, announces that as the flagship event of HKTDC's E-commerce Express, the second Hong Kong Shopping Festival will partner with major e-commerce and social media platforms for promotion and include a series of training sessions focused on the Mainland e-commerce market.Irina Fan, HKTDC Director of Research, said over 60% of surveyed Hong Kong businesses view the Mainland Chinese market as the most promising e-commerce market in the coming one to two years.Samantha Ko Hoi Ling, Artist, attends the launch ceremony of the Hong Kong Shopping Festival, promoting Hong Kong’s brands and products.Media EnquiriesYuan Tung Financial Relations:Louise Song Tel: (852) 3428 5691 Email: lsong@yuantung.com.hkTiffany Leung Tel: (852) 3428 2361 Email: tleung@yuantung.com.hk HKTDC’s Communications & Public Affairs Department:Sharon Ha Tel: (852) 2584 4575 Email: sharon.mt.ha@hktdc.orgKaty Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgHKTDC Media Room: https://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 30, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK) recently announced via the Hong Kong Stock Exchange that it repurchased 17.65 million shares through on-market transactions on July 29, 2025, with a total consideration of HK$32.301 million. The repurchase price ranged from HK$1.80 to HK$1.86 per share. This marks another substantial buyback in the past month, reflecting management’s firm confidence in the company’s intrinsic value and long-term development.According to data, since July 2025, Shoucheng Holdings has cumulatively repurchased approximately 36.746 million shares, with a total expenditure of HK$66.7313 million. In addition to the July 29 buyback, the company executed another significant repurchase on July 10, acquiring 19.05 million shares for HK$34.3464 million at a price range of HK$1.79–1.80.Share repurchases are among the strongest signals a listed company can send to the market. In the face of short-term market volatility, Shoucheng has chosen to act decisively, reaffirming its responsibility to shareholders and its long-term value commitment. Management has conveyed a clear message: the company is committed to defending its fundamentals and investor confidence with concrete capital actions.Management stated: “We remain firmly optimistic about the long-term value of Shoucheng Holdings and are confident in our strategic direction, operational foundation, and future growth. This round of repurchases reflects our duty as a listed company to our shareholders, the market, and the company itself. We will continue to step forward at key moments to stabilize expectations and fulfill our long-term commitments to investors.”As a leading smart infrastructure asset operator in China, Shoucheng has deeply invested in core business sectors including equity investment, REITs, industrial real estate, and smart parking. It has built a strong asset cycle and cash flow system. In emerging sectors such as robotics and new infrastructure, the company continues to unlock growth potential and industrial synergy.Industry observers note that in today’s undervalued Hong Kong market, Shoucheng’s large-scale repurchase sends a clear signal: the company is prepared to reward long-term investors through steady performance, solid fundamentals, and disciplined capital management—true to its role as a creator of long-term value.With strong fundamentals and buybacks reinforcing support, Shoucheng Holdings’ future market performance is worth watching.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

Naoris is Spearheading the First Decentralized Post-Quantum Infrastructure for Web2, Web3 & Web 4WELLINGTON, FL, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, the first in production quantum-resistant blockchain and cybersecurity mesh architecture, has announced its upcoming TGE for July 31, 2025, marking a key milestone in the rollout of a new foundational security layer for the internet, designed to protect both Web3 and Web2 ecosystems from quantum and traditional threats. The $NAORIS token will launch for trading on July 31 at 12:00PM UTC / 08:00AM ET. At TGE, the initial circulating supply will be 599.260,000 NAORIS tokens, with a fully diluted valuation (FDV) of $500M FDV. The token will be available for trading on Binance Alpha, Binance Perps, and Gate.io with additional exchange listings to be confirmed. For the latest details, visit the Naoris Protocol website on July 31.In terms of utility, the $NAORIS token powers a machine-driven trust economy, enabling real-time, quantum-resistant security validations across both Web3 and traditional Web2 infrastructures. Embedded at the Sub-Zero layer within a Decentralized Trust Mesh, $NAORIS powers autonomous device-to-device security challenges that trigger token swaps per block, ensuring continuous, automated trust without human input. Each node earns influence and rewards based on its trust score, creating a dynamic consensus system rooted in behavior and reliability. Token holders can stake to secure the network and participate in governance, aligning incentives with long-term protocol resilience.The announcement comes just weeks after Naoris raised $3 million in a strategic funding round led by Mason Labs, with participation from Frekaz Group, Level One Robotics and Tradecraft Capital.The $NAORIS token is the core utility asset powering this infrastructure, enabling access to security services, governance and incentives for network participants. As the lifeblood of the Naoris Protocol, $NAORIS serves as the cyber-trust primitive that drives decentralized security infrastructure across blockchains, enterprises and IoT ecosystems.Operating at the Sub-Zero Layer, beneath L0 to L2 blockchains, Naoris Protocol provides the trust and security fabric for decentralized applications and existing internet infrastructure. It integrates directly with EVM-compatible blockchains without requiring hard forks and extends protection to blockchain transactions, physical infrastructure, including enterprise systems, cloud platforms, IoT devices, validators, bridges and decentralized exchanges. Naoris Protocol’s Post-Quantum technology is aligned with NIST, NATO and ETSI post-quantum standards – the US Government has mandated that all digital systems transition to post-quantum cryptographic standards by 2030, with legacy algorithms fully phased out by 2035.“At Naoris, we firmly believe that blockchains cannot retrofit their way to post-quantum security, they must be built into the infrastructure from the ground up,” said Naoris CEO and Founder David Carvalho. “Our TGE helps us move closer to delivering the next standard in cyber-resilient infrastructure,ensuring global systems remain secure in the post-quantum era.”Naoris’ architecture combines Post-Quantum Cryptography, Decentralized Proof-of-Security (dPoSec) consensus, and Swarm AI to secure blockchain transactions and web infrastructure against quantum computing risks. Key features include:Quantum-Secure Blockchain Transactions: Enhances EVM blockchains against quantum threats without network disruptions.Trusted Web3 Infrastructure: Immutable, real-time mesh network secures nodes, validators, bridges, and DEXs.Distributed Web2 Security: Converts all devices into validator nodes, forming a self-healing network without single points of failure.Since launching its testnet in January, Naoris Protocol has recorded significant growth, with over 100 million post-quantum transactions processed, over 3.3 million wallets onboarded, over 1M security nodes and over 475 million cyber threats mitigated as well as 31 active projects under development across sectors such as finance, telecom, energy, defense, and IoT.Alongside CEO and Founder David Carvalho, Naoris Protocol is guided by a leadership team with deep expertise across cybersecurity, defense, and blockchain verticals, bringing together a diverse range of global experience. The team includes David Holtzman, former CTO of IBM and a key architect of the DNS protocol; Ahmed Réda Chami, Ambassador of Morocco to the European Union and former CEO of Microsoft North Africa; Mick Mulvaney, former White House Chief of Staff; and Inge Kampenes, retired Major General and former Chief of the Norwegian Armed Forces Cyber Defence. Their combined backgrounds reflect the protocol’s focus on building secure, scalable infrastructure for both Web3 and traditional systems.To learn more about Naoris Protocol, users can visit https://www.naorisprotocol.com/ About Naoris ProtocolNaoris Protocol is the world’s first Decentralized Post-Quantum Infrastructure, built to secure both Web3 and Web2 against traditional and quantum threats. Operating beneath blockchain layers 0 to 3 as a Sub-Zero Layer, it integrates with existing EVM chains, nodes, bridges, dApps, enterprise systems, and IoT devices without requiring hard forks.Media Contact: sharon@babslabs.io Disclaimer: All product and company names herein may be trademarks of their registered owners. The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Copyright 2025 ACN Newswire via SeaPRwire.com.

HAYWARD, CALIFORNIA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog's acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical, microbiome, and agricultural markets.Today, Biolog's TruPRAS™ media is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, preventing the formation of harmful byproducts that can be toxic to anaerobic organisms. This line of media products, which has been approved for In Vitro Diagnostic (IVD) use by the USA FDA for years, has now also achieved CE marking under the requirements of the EU IVDR regulation 2017/746. With zero recalls or field actions throughout their extensive history, these products enable transport of specimens and growth of fastidious anaerobes that play important roles in disease pathology - supporting clinical diagnostics in medical laboratories."The IVDR/CE mark is a major milestone that recognizes the high standard of our anaerobic media and its value in supporting critical diagnostic workflows," said Robert Wicke, CEO at Biolog. "We're proud that clinical labs throughout Europe can now benefit from the same reliable performance that researchers and clinicians in the U.S. have trusted for decades."Biolog's anaerobic chambers have also received the CE mark, affirming their safety and performance for use in any research settings throughout the world. With unique InstaSleeve™ technology, these ergonomic, gloveless chambers offer superior processing dexterity while working in a fully anaerobic environment and are a preferred tool for microbiologists in both clinical and academic settings. In addition, Biolog is releasing an upgrade to enable hypoxic or microaerophilic conditions in the same chamber, for organisms that require specific, low concentrations of oxygen to thrive."This dual achievement reinforces Biolog's commitment to advancing global access to high-quality tools for anaerobic microbiology," said Wicke. "Whether you're working with challenging clinical isolates or conducting fundamental research, Biolog now provides dependable CE-marked solutions that meet your needs."About BiologBiolog offers tools, services, and support for comprehensive cellular characterization and multi-omic identification of bacteria, yeast, and fungi. Our products also enable phenotypic profiling of microbial and mammalian cells for a range of applications, including supporting the culture of fastidious anaerobes with our line of gloveless chambers and pre-reduced media. Learn more at biolog.comContact InformationJohn Proctor, Ph.D.CCOjproctor@biolog.com(408)306-0414SOURCE: Biolog, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - July 25, Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, stock code: 1788.HK), a company of Guotai Haitong Group, is pleased to announce that while actively saving energy and reducing emissions，it has successfully offset its Scope 1 and Scope 2 carbon emissions totaling 609.29 tons of carbon dioxide equivalent for the year 2024 by subscribing to the carbon credits issued under the international Verified Carbon Standard (VCS). This marks the third consecutive year that GTJAI has achieved “carbon neutrality” at the operational level, demonstrating the Company's leading practice and commitment to green operation.The carbon credits come from “Guoluo Grassland Sustainable Management Project” located in Guoluo Tibetan Autonomous Prefecture, Qinghai Province, China. It is dedicated to the restoration of degraded grassland ecosystems, based on the holistic nature of the ecosystems, in line with the concept of ecological civilization construction, and to effectively respond to the challenges of climate change. The project is also the first grassland carbon project in China receiving both VCS certification and the Climate, Community and Biodiversity Standards (CCB) - CCB-Biodiversity Gold Level certification.In recent years, GTJAI has been continuously reducing its operational carbon footprint through systematic energy saving and emission reduction initiatives, which is the core support for the achievement of “carbon neutrality”, including vigorously implementing energy-saving renovation of office space, deepening digitalization and paperless transformation, and implementing stringent waste management (100% safe recycling of hazardous waste by 2024). Solid internal emission reduction efforts, combined with carbon offsetting through high-quality carbon credits, enabled the Company to achieve “carbon neutrality” at the operational level.Adhering to the core philosophy of “finance for the country, finance for the people, finance for the good”, GTJAI has always placed sustainable development at the core of its corporate strategy. The Company is committed to supporting the real economy through financial services while facilitating the green transformation of its corporate clients. In 2024, the Company successfully completed 90 sustainable finance projects covering green bonds, sustainable bonds and green sector IPOs with a total issuance volume of HK$179.8 billion, significantly broadening the financing pipeline for the green industry. Meanwhile, the private equity sector is actively engaged in the sustainability sector, with more than half of its investments focusing on ESG-related industries.Looking ahead, GTJAI will deepen the level of ESG governance, fully integrate ESG factors into its operations and management processes, further leverage its professional strengths and enhance the level of green financial services capabilities. Through innovative products and services, GTJAI will proactively contribute to the realization of the country's “dual carbon” goal and promote the high-quality development of the economy and society.About GTJAIGuotai Junan International (“GTJAI”, Stock Code: 1788.HK), a company of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes brokerage, corporate finance, asset management, loans and financing, financial products, which cover three dimensions including individual finance (wealth management), institutional finance (institutional investor services and corporate finance) and investment management. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH; 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com Copyright 2025 ACN Newswire via SeaPRwire.com.

ANKARA, Turkey, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC®) in Toronto.This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20).The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease.No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%).Abidin Gülmüs, Chairman of GEN, stated:"We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease."Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added:"With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease."About SUL-238SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's "powerhouse." It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications.About GEN:Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments.About Sulfateq:Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health.For more information:www.genilac.com.trwww.sulfateqbv.comContact InformationBulutay GünesSr. Head of Corporate Brandb.gunes@genilac.comAli KetenciogluInvestor Relations Managera.ketencioglu@genilac.comKees van der GraafSulfateq CEOinfo@sulfateqbv.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - July 28, 2025) - Doubleview Gold Corp (TSXV: DBG) (OTCQB: DBLVF) (WKN: LA1W038) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce the commencement of an advanced exploration program at its 90%-owned copper-silver-zinc-gold Red Spring Project, located in central British Columbia, Canada. This initiative marks a significant step in unlocking the project's full potential and reinforces Doubleview's commitment to critical mineral development.Red Spring Project: Inaugural 3D IP Survey UnderwayThe Red Spring Project, a pillar in Doubleview's expanding portfolio, is situated in a highly prospective region of central British Columbia, Canada. The Company holds a 90% interest in this compelling copper-silver-zinc-gold project, which has demonstrated strong mineralization in historical drilling, particularly in its central zone. Decades of previous operator activities, including sampling, geophysical surveys, and approximately 4,000 feet of drilling, have laid the groundwork for Doubleview's current advanced exploration. The project is strategically important to the Company as it strengthens its emphasis on critical minerals.The first phase of Doubleview's 2025 exploration program at the Red Spring property comprises an inaugural 3D Induced Polarization (IP) survey. This state-of-the-art three-dimensional geophysical survey will target the Angus Zone, an area of high interest previously sampled and prospected by the Company. The survey is expected to be completed by the end of August 2025.The 3D IP survey will provide valuable insights into the subsurface geology and will contribute to planning and guiding future drill programs. Farshad Shirvani, President and CEO of Doubleview Gold Corp, commented: "Due to significant third-party interest in the Company's flagship HAT project, management is strategically advancing exploration at its Red Spring Project, as it has consistently demonstrated strong potential, both historically and through Doubleview's past exploration efforts. The 3D IP program will provide detailed information and valuable insights with minimal environmental impact. Our goal is to gain a better understanding of the deposit, expand the area of interest, and help define precise targets for further work, including drilling. The Red Spring Project is an important component in Doubleview's portfolio of properties and emphasizes our focus on critical minerals."Doubleview is dedicated to collaborative engagement with local stakeholders and First Nations and strives to apply sustainable exploration methods that ensure minimal land impact.Hat Polymetallic Deposit UpdateExploration and definition of Doubleview's flagship Hat Project continues with 2025 drilling surpassing 6,500 meters. Drill hole H099, currently in progress, is approaching the significant 100 drill hole milestone. The preliminary economic assessment (PEA), metallurgy, and environmental baseline studies are continuing and underscore the comprehensive advancement of this significant polymetallic deposit.About Doubleview Gold Corp With active programs at both the HAT and Red Spring projects, Doubleview anticipates that 2025 will be its most productive year to date, reflecting the Company's robust and exciting exploration and development activities.Doubleview Gold Corp, trading on the TSX-Venture Exchange (TSXV: DBG) (OTCQB: DBLVF) (WKN: LA1W038) (FSE: 1D4) is a Canadian-based mineral resource exploration and development company focused on the discovery and advancement of high-value mineral deposits in British Columbia. The Company controls a portfolio of prospective mineral properties, including the Hat polymetallic deposit and the Red Spring copper-gold-silver project.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive Officer For further information please contact: Doubleview Gold Corp Vancouver, BC Farshad Shirvani President & CEO T: (604) 678-9587E: corporate@doubleview.caWebsite: www.doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information". In particular references to the private placement and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260280 Copyright 2025 ACN Newswire via SeaPRwire.com.

Tokyo, Japan, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - Quantum Solutions Co., Ltd. (2338.T) and its affiliates (the “Quantum Solutions’ Group” or “Quantum Solutions”), a Tokyo Stock Exchange-listed company, today announced a new strategic milestone in its digital asset initiative. The Quantum Solutions’ Group, has entered into a business collaboration arrangement with TDX Strategies Ltd, a renowned digital asset technology company in Asia. The two parties will cooperate extensively in areas including Bitcoin trade execution, asset custody, structured product design, and market risk management—offering end-to-end technical and service support for Quantum Solutions’ Bitcoin Treasury strategy.Quantum Solutions previously disclosed its plan to accumulate up to 3,000 Bitcoins over the next 12 months, aiming to hedge inflation risks, optimize asset structure, and enhance the agility of its financial system. The collaboration with TDX Strategies marks a key transition from capital planning to systemized execution and is expected to substantially strengthen the Quantum Solutions’ technical capabilities and operational security in the management of digital assets.TDX Strategies is a tech-driven enterprise focused on trading and structuring of digital financial products. It holds licensed investment trading and operational status in the British Virgin Islands (BVI). With a strong track record in blockchain asset operations and a robust institutional network across markets, TDX serves a range of Asian family offices, asset managers, and corporate clients. For this collaboration, Quantum Solutions’ Group agrees to prioritize the selection of TDX’s paid cryptocurrency services on a non-exclusive basis, ensuring operational flexibility and execution reliability for the Treasury business.According to the agreement, TDX Strategies will provide comprehensive support to Quantum Solutions’ BTC Treasury business, including: assisting in the development of an institutional-grade trade execution system tailored for Bitcoin; establishing enterprise-level cold/hot wallet management frameworks and multi-signature security protocols to safeguard custody; designing principal-protected and yield-enhancing structured products based on Bitcoin holdings to improve capital efficiency; and delivering ongoing consulting in operational, technical, risk exposure control, and market response strategies.TDX Strategies is recognized as a next-generation digital asset firm with hands-on expertise in structured finance instruments, institutional trading infrastructure, and cross-chain solutions. Its team combines deep knowledge in blockchain application development and traditional risk management, and the company enjoys a strong reputation in the Asian crypto-financial space. Notably, TDX is one of the portfolio companies under a strategic partner of Quantum Solutions Mr. Tak Cheung Yam, the ultimate beneficial majority shareholder of renowned American media Forbes Media LLC a .Mr. Yam is also the sole owner of Integrated Asset Management (Asia) Limited, which recently extended a USD 10 million loan to Quantum Solutions’ Group to support the initial phase of its Bitcoin Treasury initiative. As a globally respected investor, Mr. Yam has committed both capital and infrastructure to accelerate Quantum Solutions’ entry into the digital asset space. Through this partnership, TDX Strategies’ technological resources and professional team have also been made available to Quantum Solutions, reflecting Mr. Yam’s full-spectrum commitment—both financially and operationally.Quantum Solutions noted that the collaboration establishes a comprehensive support system for its digital asset strategy—spanning funding, infrastructure, and compliance. This creates a closed-loop model from capital infusion to asset management, and represents a clear shift from “reserve asset” to “strategic asset” status for Bitcoin within the company’s evolving financial framework. The initiative is designed to deepen the asset’s integration into the corporate finance structure while maximizing its intrinsic and strategic value.Looking ahead, Quantum Solutions and TDX intend to expand their collaboration to cover a wider range of use cases, including Bitcoin yield strategies, stablecoin allocations, and cross-chain structured product development. These efforts aim to further enhance the flexibility and compounded value potential of the company’s digital asset portfolio.This partnership marks not only the operational execution of the company’s digital asset strategy, but also a significant step forward in building a future-ready financial architecture. As the Bitcoin Treasury program advances, Quantum Solutions expects to accelerate the development of an enterprise-grade reserve framework that is institutionalized, auditable, and responsive to market conditions—providing robust safeguards for long-term asset security and corporate growth.About Quantum Solutions Co., Ltd.Quantum Solutions Co., Ltd. (Tokyo Stock Exchange: 2338.T) is a Tokyo-based high-growth technology company specializing in artificial intelligence, big data analytics, and blockchain-related innovation. Founded in 2004 and listed on the Tokyo Stock Exchange, the company delivers advanced technology solutions across a range of industries, including fintech, healthcare, and smart manufacturing. In its financial year ended 28 February 2025, Quantum Solutions reported approximately USD 4.7 million in revenue and is currently holdings over several trademarks and patents in games. For more information, please visit: https://www.quantum-s.co.jp/en/corporateForward-Looking StatementsThis press release contains forward-looking statements based on information currently available to the company and certain assumptions regarding future events and expectations. These statements are subject to various risks and uncertainties—including but not limited to changes in policy, market conditions, technological developments, and regulatory factors—that could cause actual results to differ materially from those expressed or implied in such statements. Existing and prospective investors are advised to consider potential risks carefully and not to place undue reliance on any forward-looking statements contained herein. Such statements speak only as of the date of this release. Unless required by law, the company undertakes no obligation to update or revise any forward-looking statements in light of new information, future events, or other circumstances.For further enquiries, please contact:Hong Kong/International:Mr. Steven TungEmail: steven.tung@quantum-s.co.jpJapan:Ms. Linda PengEmail: linda.peng@quantum-s.co.jp Copyright 2025 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.About Product ZUNVEYLZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. As the second oral therapy approved by FDA for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better gastrointestinal safety profile to improve compliance of Alzheimer’s disease patients and therefore brings clinical benefits. Patent in regard to use of ZUNVEYL has already been granted in China.About Alzheimer’s DiseaseAlzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, and drug intolerance is one of the challenges in current treatment of Alzheimer’s disease. Tolerability affects therapy adherence, with data showing that 55% of Alzheimer’s disease patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among patient’s family, physicians, and caregivers[9]. Therefore, Alzheimer’s disease patients still have an urgent need for safer therapies.On 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type. In accordance with the Agreement, the Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East region), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years (the “Initial Term”), it may be automatically renewed every five years upon the expiration of the Initial Term unless terminated by notice from either party.Around six months after obtaining the above rights of ZUNVEYL, the Group promptly submitted the NDA in China, demonstrating its efficient allocation of resources and robust capabilities in registration promotion. ZUNVEYL will further diversify the Group’s innovative drug product matrix and enhance the Group’s comprehensive competitiveness. The Product will synergize with the Group’s various central nervous system products including the innovative drug VALTOCO (diazepam nasal spray) and the original brand drug Deanxit (flupentixol and melitracen tablets) on sale and the innovative drug Y-3 for Injection under development in terms of expert network and market resources. Relying on the Group’s successful commercialization experience and compliant and efficient commercialization system, if ZUNVEYL is approved for marketing, it will bring a new drug option for the treatment of cognitive impairment in Chinese Alzheimer’s disease patients, meeting the clinical need for drugs of both efficacy and safety, improving disease diagnosis and treatment practices, thereby benefiting patients. The Product is expected to have a positive impact on the Group’s financial results.Reference:1. Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.00000000000118322. Safety profile of ZUNVEYL as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease- 3. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0034. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer's Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0045. Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-76. Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.7. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-200481038. Research Report on the Diagnosis and Treatment of Alzheimer’s Disease Patients in China (2020). Alzheimer's Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html9. Data on patient discontinuation as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease-About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

- The HKTDC continues to help SMEs seize digital trade opportunities by co-hosting with the ICC DSI a masterclass on technologies such as electronic bills of lading and blockchain. More than 200 SMEs took part.- Prof Frederick Ma, Chairman of the HKTDC, emphasised that Hong Kong is actively developing its digital trade ecosystem, with a focus on innovation, efficiency and international collaboration, to consolidate its competitive advantages. As digital trade becomes more common, the HKTDC will ensure Hong Kong businesses continue to thrive and enhance the city’s role as a leading supply chain hub.- Pamela Mar, Managing Director of ICC DSI, noted that by aligning its finance, trade and logistics sectors with global digital trade standards, Hong Kong can remain competitive and resilient on the world stage and is well-positioned to spearhead Asia’s digital-trade development.- Andy Lam, Deputy Secretary for Commerce and Economic Development of the HKSAR Government, said that the Government is making reference to the Model Law on Electronic Transferable Records and is considering legislative amendments to remove the legal hurdles in the digitalisation of trade documents. The target is to submit the relevant legislative proposal to the Legislative Council next year to help industry develop technical solutions based on their actual needs.HONG KONG, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - Digitalisation is reshaping the global economy, and companies must embrace digital transformation to capitalise on new opportunities. The 2025-26 Budget announced that the Hong Kong Special Administrative Region (HKSAR) Government would make reference to the Model Law on Electronic Transferable Records (MLETR) advocated by the United Nations Commission on International Trade Law (UNCITRAL) and consider legislative amendments to facilitate digitalisation of trade documents. The legislative proposal will be submitted to the Legislative Council next year. The MLETR is a global standard advocated by the UNCITRAL to provide a legal framework for electronic trade documents. Aligning local legislation with standards of the MLETR is a major endeavour in promoting trade digitalisation. In line with these efforts, the Hong Kong Trade Development Council (HKTDC) and the International Chamber of Commerce Digital Standards Initiative (ICC DSI) co-hosted the “Digital Trade Masterclass” at the Hong Kong Convention and Exhibition Centre to examine the MLETR’s potential impact on Hong Kong’s cross-border trade. Industry experts shared practical insights on digital transformation, helping equip businesses with the information they need to enhance their high value-added service capabilities. More than 200 SMEs participated in the event.As an international financial and trading centre and a leading re-export hub, Hong Kong is able to capitalise on its unique advantages to reinforce connectivity, serving as a bridge linking the mainland and global markets. It provides high-standard professional services, robust financial infrastructure and an innovative environment for international trade. The HKTDC works closely with the HKSAR Government to highlight the city’s strength in delivering high value-added services across the trade supply chain.Speaking at the event, Prof Frederick Ma, Chairman of the HKTDC, said that with the changing trade landscape, there was no better time to reinforce Hong Kong’s competitive advantages. “Hong Kong is actively developing its digital trade ecosystem, with a focus on innovation, efficiency and international collaboration, to consolidate its competitive advantages. As digital trade becomes more common, we are committed to making sure Hong Kong businesses continue to thrive. It is also a great opportunity to reinforce our city’s role as a leading supply chain hub. The HKTDC is dedicated to helping businesses leverage innovative technologies to equip businesses to be future-ready. Our Asian Logistics, Maritime and Aviation Conference (ALMAC) examines trends in global trade and supply chains, innovation and digitalisation, while our support programmes, including Transformation Sandbox, help enterprises scale up their capabilities in key areas, including digital transformation and supply chain solutions, to empower SMEs and start-ups to benefit from digital trade.”Pamela Mar, Managing Director of the ICC DSI, believes Hong Kong, as an international trade and logistics hub already aligned with global standards, will lead Asia’s future digital trade development by remaining competitive and resilient amid a shifting global landscape. “Finance, trade and logistics make up over 45 % of Hong Kong’s economy, so accelerating digitalisation in these sectors will have a positive economy-wide impact.”, said Pamela Mar. “Hong Kong is well-positioned to become a leader in this space by aligning global standards and building on its strength as a trusted hub. The adoption of MLETR is a vital step, providing legal certainty for electronic documents like bills of lading, while streamlining processes and enhancing traceability. But legal reform is only the beginning — even greater gains lie in the private sector stepping up its digital transformation, which can be enhanced by Web3 technologies.”Andy Lam, Deputy Secretary for Commerce and Economic Development of the HKSAR Government, said, “The HKSAR Government is committed to fostering an efficient business environment and maintaining the international competitiveness of Hong Kong. Facilitating the digitalisation of trade documents is part of this strategy. We anticipate that the industry would actively provide feedback and allow the Government to formulate a legal framework that is in line with the needs of the industry, on which basis the industry may propose different technical solutions. On the other hand, the Government is also pressing ahead with Phase 3 of the Trade Single Window, which will not only facilitate the industry in their submission of business-to-government trade documents such as import and export declarations, but will also connect with the Hong Kong Monetary Authority (HKMA)'s Commercial Data Interchange (CDI) to facilitate banks in accessing relevant data to process trade financing.”Industry experts discuss challenges in trade digital transformationAccelerating digital transformation across every link of the supply chain introduces unique challenges. At the Masterclass, the conference brought together specialists in digital trade finance, electronic bills of lading, digital freight and logistics, and digital retail supply chain management to share their practical experience and insights working on digital transformation.Kenise Sin, Senior Data Analyst in the Financial Infrastructure Department at the HKMA, explained: “SMEs’ access to trade finance has long been hindered by different pain points in the process. For instance, the heavy reliance on paper-based documents has led to inefficiencies and difficulties in tracking and verifying the transactions.” She added that HKMA aims to formulate a digitalisation roadmap for sea, road and air transportation cargo data by the end of this year, integrating cargo data sources across jurisdictions with the HKMA’s CDI, to enhance data sharing. In the coming two years, the HKMA will also work with the Airport Authority Hong Kong, the Transport and Logistics Bureau as well as pilot banks to leverage cargo data and CDI to improve digital trade finance.Erik Kwok, Head of Technology and Operations at Air8 — which develops a supply chain finance platform for cross-border trade — echoed these concerns: “Many small to medium-sized exporters struggle to secure funding due to inadequate data for credit assessments, hindering their ability to compete globally. These obstacles are compounded by insufficient support for risk management strategies, leaving SMEs vulnerable in a rapidly evolving market.”Another guest speaker, Candy Chan, Product Manager at IQAX, outlined how digitalising bills of lading can save both time and costs, boosting the efficiency of the entire trade ecosystem. She said many banks, freight forwarders, and customs systems still operate on fragmented digital platforms and lack interoperability. Blockchain, she argued, can bridge these silos: “Each trading partner has unique operational needs when adopting blockchain networks in digital platforms. In cross-border trade, trading and shipping documents are exchanged, and digitalised documents within a blockchain network can solve trust issues within and across networks, backed by MLETR.”Photo download: http://bit.ly/4lNB4t9Prof Frederick Ma, Chairman of the HKTDC attended the Digital Trade Masterclass and delivered the opening remarks on 28 July.(From left) Andy Lam, Deputy Secretary for Commerce and Economic Development, HKSAR Government; Prof Frederick Ma, Chairman of the HKTDC; and Pamela Mar, Managing Director, ICC DSI.Industry experts shared insights and challenges on digital transformation. Picture shows guest speakers from the Digital Trade Masterclass with the officiating guests.(From left) Kenise Sin, Senior Data Analyst, Financial Infrastructure Department, HKMA; Jack Lee, Chief Operating Officer, GS1 Hong Kong; Bertrand Chen, Chief Executive Officer, Global Shipping Business Network; Andy Lam, Deputy Secretary for Commerce and Economic Development, HKSAR Government; Prof Frederick Ma, Chairman of the HKTDC; Pamela Mar, Managing Director, ICC DSI; Ivy Tse, Co-Chief Executive Officer & Co-founder, FreightAmigo; Erik Kwok, Head of Technology and Operations, Air8; and Candy Chan, Product Manager, IQAX.Over 200 SMEs attended the Digital Trade Masterclass, reflecting strong interest.Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Johnny TsuiTel: (852) 2584 4395Email: johnny.cy.tsui@hktdc.orgWinnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit:www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI July 28, 2025 - (ACN Newswire via SeaPRwire.com) - 26th July 2025, CITIC Telecom International Holdings Limited (“CITIC Telecom”, SEHK:1883), Asia-Pacific leading multinational Internet-oriented telecommunications enterprise, has joined hands with its subsidiaries including Companhia de Telecomunicações de Macau, S.A.R.L. (“CTM”), CITIC Telecom CPC and China Entercom to exhibit at 2025 WAIC (World AI Conference) for four years in a row.The theme of this year's conference is “Global Solidarity in the AI Era”. In tune with the zeitgeist and guided by CITIC Group’s philosophy, “CITIC, Your Trusted Partner for Going Global and Coming to China”, CITIC Telecom focuses on the strategic direction of “AI+ Connect for Global Reach”. At the WAIC 2025, a compelling display of breakthroughs were showcased, including empowering intelligent business upgrades, enhancing connectivity in digital economies, reinforcing the dual strategies of “Going global” and “Coming to China” market flows, and integrating AI more deeply into real-world industry scenarios.CITIC Telecom continues to play a vital bridging role by actively engaging in the global technology ecosystem enabling Chinese enterprises to pursue “Going Global” strategies while accelerating international enterprises in “Coming to China”, fueling the growth of intelligent technologies.Smart CITIC: Creating Possibilities TogetherCITIC Group participated prominently in this year’s WAIC under the theme “Smart CITIC: Creating Possibilities Together”. Leveraging its integrated strengths in “Technology, Industry & Finance”, the Group showcased a wide range of innovative AI applications and industry-specific AI solutions across technological innovations, emerging industries, financial empowerment, and internationalization. As a key component and strategic pillar of CITIC’s new consumption segment, CITIC Telecom significantly contributed to the “Technology Innovation” and “Internationalization” zones. With close collaboration among its subsidiaries, the exhibit demonstrated its robust foundational tech capabilities, industrial empowerment and ecosystem synergy. It has further unlocked high-quality AI-driven growth, providing CITIC’s intelligence and smart solutions to enhance digitization in China and connect global digital economies. Additionally, a series of on-site “CITIC AI+ Practice Sharing” sessions offered valuable insights into the practical applications and commercial potential of its innovations. “AI+ Connect” for Global Reach: Powering the Next Engine of High-Quality DevelopmentAmidst rapid global digital growth, CITIC Telecom, an important cornerstone of CITIC Group’s international business, is actively embracing China’s “AI+” and high-standard opening-up strategies. It also focuses on fostering a globally interconnected digital ecosystem, deepening the two-way pathways for “Going global” and “Coming to China”, and contributing to a more open, trusted, and mutually beneficial global digital landscape.To realize this strategic vision, CITIC Telecom has established a robust global presence across five continents, comprising nearly 170 Points of Presence, 21 Cloud Service Centers, over 30 Data Centers, and three 24x7 Security Operations Centers (SOCs). These resources and infrastructure support highly responsive, global coverage, agile, digital and intelligent cloud-network-security services. Therefore, it not only provides cybersecurity protection and intelligent connectivity for both central state-owned enterprises and Chinese enterprises going global, but also delivers fast and reliable localized services to multinational corporations, positioning CITIC Telecom as a vital bridge connecting global and local markets, industries and technologies.To further its localization strategy and capability, CITIC Telecom has enhanced regional collaboration through its subsidiaries. ACCLIVIS, operating extensively across ASEAN markets, has accelerated AI, cloud security and cybersecurity deployments in critical sectors such as healthcare and manufacturing, which has infused the Southbound Corridor with sustained innovation momentum. In Greater Bay Area, CTM plays a pivotal role in the “Digital Macau” initiative targeting focus on enabling the moderate economic diversification of Macau, promote smart government, smart campus, smart transformation of various fields. Harnessing the convergence of AI and telecom technologies, it has become a powerful digital and intelligent engine driving Macau’s high-quality development.CITIC Telecom has empowered over 3,000 Chinese and international enterprises in their cross-border development, serving more than 40,000 local clients worldwide, including over 200 Fortune Global 500 enterprises. This highlights the leap from vision to execution in its global strategy, forging partnerships to shape an interconnected digital future.Harnessing Technology: Empowering the Future of “AI+ Connect”In constructing a globally interconnected digital ecosystem, CITIC Telecom is fortifying its innovation foundations to support the next-generation digital framework for enterprises. Leveraging its extensive technological expertise and innovative R&D framework, it is exploring key areas such as AI+ Big data, AI+ Networking, and AI+ Large Model applications, continuously launching scalable, deployable solutions.In the field of AI data governance, AI Databank integrates Big Data, AI, Large Language models (LLMs) and generative AI to create a unified data platform that eliminates silos and enables seamless cross-system integration. Its innovative AI data governance technology has gained widespread adoption across industries and earned the Silver Medal at the 50th International Exhibition of Inventions Geneva in 2025, highlighting CITIC Telecom's excellence in AI research and innovation.In the realm of network services, the “AI Roaming Data Acceleration Pack” project significantly enhances global data transmission efficiency and stability for multinational enterprises by optimizing routing paths and network nodes. By integrating cutting-edge intelligent technologies with the GSMA Open Gateway standards, this solution has been successfully implemented in smart tourism across Hong Kong and Macau. Its innovative approach also earned the Third Prize in the “Open Gateway Global Use Case Innovation Challenge”.In the area of smart living, CITIC Telecom featured CTM’s pioneering “Smart City” project and its 10 Gigabit network infrastructure development in Macau. Powered by a dual-engine approach combining F5G-A and 5G-A technologies, CTM has built Macau’s first “10 Gigabit All-Optical Network Smart Neighborhood”, achieving full gigabit network coverage in Macau citywide. It enables a number of intelligent applications and drives the digital transformation of public services and urban governance, as well as exemplifying a sustainable, people-centric model of urban innovation. This “Smart City” project has garnered multiple prestigious awards both domestically and internationally, underscoring its contribution to the vision of “Digital Macau” and aligning with national strategies for technological advancement.With full-lifecycle AI service capabilities, CITIC Telecom is creating a robust innovation chain — from foundational infrastructure to advanced applications — to empower industries in their digital and intelligent transformation. This drives enterprises success in the global market.AI+ Connect: Fortifying Data Security and Compliance for a Trusted Digital WorldTechnology continues to accelerate global expansion for businesses, yet it also brings rising concerns over data protection and regulatory compliance. CITIC Telecom has established a comprehensive data security and compliance system for the AI era, aligning with China’s Data Security Law and Personal Information Protection Law, as well as international regulations such as the EU’s General Data Protection Regulation (GDPR) and ASEAN's Personal Data Protection Act (PDPA). With this forward-looking approach, the company has addressed key challenges such as cross-border data transmission, data protection, and financial risk control, providing end-to-end protection to build a trusted and intelligent digital world.To empower the future with intelligence, CITIC Telecom shared multiple lightweight AI+ applications that integrate the strengths of “Technology, Industry & Finance” during the “CITIC AI+ Practice Sharing” sessions, all tailored to empowering global enterprises.“Intelligent Financial Fraud Shield”: Financial Fraud, particularly in cross-border transactions, has become a pressing concern. CITIC Telecom’s “Intelligent Financial Fraud Shield” introduces multi-layered identity verification and real-time transaction monitoring to combat fraudulent behavior in cross-border transactions, effectively safeguarding assets for financial institutions and end users. This solution demonstrates the company’s innovative leadership in the digital finance area.“AI+ Connect: Cybersecurity Redefined with Precise Analysis”: CITIC Telecom has developed an all-round, multi-layered intelligent cybersecurity framework to enhance cyber defense. To effectively prevent external threats and data breaches, its AI Pentest simulates real-world attacks and scans for vulnerabilities, enabling proactive threat detection and remediation. Supported by three self-deployed, self-managed AI-driven Security Operations Centers (SOCs), the system constructs a robust and resilient defense that integrates machine learning, big data analytics and large model technologies for real-time threat monitoring and automated response. Meanwhile, the “AI Guardrail” spans from endpoint to transmission layers, guarding against unauthorized access and cross-border data leaks.“AI+ Connect: From Technology Empowerment to Data Empowerment”: Harnessing patented innovations, CITIC Telecom applies intelligent algorithms and big data analytics to help enterprises streamline data governance, integrate cross-system resources, and automate intelligent analytical reports. These capabilities also support diverse small-scale AI applications leveraging large model technologies, from data collection and monitoring to compliance reporting. Through a unified data platform, the company is reimagining enterprise-grade data governance architecture with cutting-edge technologies.Moving forward, CITIC Telecom remains committed to “Connecting the world” and advancing the “AI+ Connect” for enterprises. By leveraging the CITIC Group’s financial, technological and industrial synergies, the company will continue to deepen its AI investments, accelerating the transformation of applicable, manageable, and reliable technologies into real-world solutions. As global cooperation in the smart era grows, CITIC Telecom strives to be a pivotal bridge connecting China and the world, facilitating high-standard opening-up strategies and supporting Chinese enterprises expand globally.Visit Our Booth at H2-A308In this era of digital intelligence, technological innovation stands as the core driver of enterprise resilience and national progress. Embracing this spirit, CITIC Telecom is fast-tracking its technological roadmap to expand its global “Tech+” presence by integrating AI, big data, cloud computing and cybersecurity. We look forward to partnering with industry peers to ignite the future of intelligence and shape a world of shared success.For more details on “CITIC AI+ Practice Sharing”, please visit: https://mp.weixin.qq.com/s/svkprkpnnoC04gdsKZh9HAAbout CITIC Telecom International Holdings Limited (HKEx: 1883)CITIC Telecom International Holdings Limited was established in 1997 in Hong Kong, and was listed on the Hong Kong Stock Exchange on 3 April 2007. As one of the largest international telecommunications hubs in Asia Pacific, CITIC Telecom provides full-scale international telecommunications services to carrier clients around the globe, and integrated enterprise services in Southeast Asia through its wholly-owned subsidiary Acclivis Technologies and Solutions Pte. Ltd.CITIC Telecom International CPC Limited (“CPC”), CITIC Telecom’s wholly-owned subsidiary, provides end-to-end information and communications technology solutions to multinational corporate clients and business clients. CPC is one of the most trusted partners of these clients in the Asia-Pacific region, and provides a full range of ICT services to major enterprises and multinational corporate clients in Chinese mainland through its subsidiary China Enterprise ICT Solutions Limited.CITIC Telecom holds 99% equity interest in Companhia de Telecomunicações de Macau, S.A.R.L. (“CTM”). CTM is one of the leading integrated telecommunications services providers in Macau, and is the only full telecommunications services and ICT services provider in Macau. With a leading position in the market, CTM plays an important role in the ongoing development of Macau. CITIC Telecom has established branch organisations in 22 countries and regions, with approximately 2,500 staff and nearly 170 PoPs, and business serving 160 countries and regions, connecting to over 600 operators globally, and serving around 3,000 multinational corporations and 40,000 local companies around the globe.CITIC Group Corporation, a large multinational conglomerate headquartered in the People’s Republic of China, is the ultimate holding company of CITIC Telecom.For more information, please visit: www.citictel.comMedia Enquiry:CITIC TelecomMs. Sylvia LiTel: +852 3423 3168Email: sylviali@citictel.comCatherine YuenCITIC Telecom CPC (852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - Phoenitron Holdings Limited (“Phoenitron” or the “Company”, together with its subsidiaries, the “Group”; stock code: 8066) announced the grant of share options to 10 eligible employees (the “Grantees”) of its two wholly-owned subsidiaries, namely Shanxi Dongchuang Digital Entertainment Technology Group Company Limited (“Shanxi Dongchuang”) and CyberMirage (HK) Limited (“CyberMirage”). This initiative recognizes the significant contributions these employees have made in driving the Group’s sustained growth and exceptional performance. The grant of share options also further aligns employees’ interests with the Group’s long-term development goals, motivates them to actively participate in the Group's future growth, enhances overall competitiveness and operational performance, and strengthens their commitment and willingness to serve the Group in the long term.An aggregate of 52,500,000 share options were granted under the share option scheme, and each option entitles the grantee to subscribe for one share. The option exercise period is 10 years commencing from the date of grant. Worthy of notice is the exercise conditions for the share options granted are linked to the performance of Shanxi Dongchuang and CyberMirage. The unaudited aggregate profits before tax of the two companies for the nine months ending 30 September 2025 have to be not less than HK$75 million, reflecting the Group’s strong confidence in the future performance and ability to meet performance targets of the two subsidiaries.About Phoenitron Holdings LimitedThe mission of Phoenitron Holdings Limited is to provide shareholders with an optimum steam of steady income and gains by best leveraging the Company’s access to capital and unique investment opportunities. Phoenitron is comprised of three primary business segments, including smartcard manufacturing services, financial consulting and recycled resources investment. Its principal activities are manufacturing and sale of smart cards, provision of customised smart card application systems, provision of financial and management consultancy services, sale and trading of scrap metals and investment in the media and entertainment industry. Headquartered in Hong Kong, the Company has primary holdings and investment across Greater China. About Shanxi Dongchuang Digital Entertainment Technology Group Company LimitedShanxi Dongchuang Digital Entertainment Technology Group Company Limited (formerly known as “Hainan Dongchuang Digital Entertainment Technology Group Company Limited”) operates a pan-entertainment digital ecosystem membership e-commerce platform, which primarily provides entertainment e-commerce with private domain traffic, including the provision of digital products and services.About CyberMirage (HK) LimitedCyberMirage (HK) Limited (formerly known as "PMIS Limited") provides artificial intelligence voice services. Copyright 2025 ACN Newswire via SeaPRwire.com.

RIYADH, KSA, July 27, 2025 - (ACN Newswire via SeaPRwire.com) - The Saudi Electricity Company (SEC) has achieved a significant milestone in its Environmental, Social, and Governance (ESG) performance, as evaluated by S&P Global. The company scored 65 out of 100, marking a 30% increase compared to its 2024 score, and an 85% improvement over its 2023 rating. This accomplishment highlights SEC's strategic progress and reinforces its position as a regional leader and a benchmark for sustainable excellence in the energy sector. Notably, SEC's score exceeds the global utilities sector average of 39 points by 66%, demonstrating its strong commitment to sustainable development. The rating reflects SEC's comprehensive institutional commitment to sustainability, driven by effective governance frameworks, ambitious strategies, and tangible improvements in environmental and social performance. SEC also showcased proactive disclosure aligned with leading international sustainability reporting standards. This progress further underscores SEC's alignment with Saudi Vision 2030, particularly in advancing sustainable energy, enhancing transparency, strengthening investor confidence, and adopting global ESG best practices. SEC reaffirmed its commitment to continuously improving its ESG performance by deeply embedding sustainability across all operations, positioning itself as a trusted and responsible energy provider both regionally and globally.Contact InformationSaudi Electricity Company (SEC)Media Relations Departmentalkahrabacare@se.com.saUnified Call Center: 920000222 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 26, 2025 - (ACN Newswire via SeaPRwire.com) - As one of the leading stock brokerage account opening offers comparison and practical investment education media platform in Hong Kong and Asia, Theinvestmedia.com ( https://theinvestmedia.com ) today proudly announced the exclusive update and launch of its fully optimized "Brokerage Account Opening Offers" special section on its website. It's also releasing a series of "Brokerage Account Opening and Platform Usage Practical Tutorials" personally written by its senior expert team. This initiative aims to empower a wide range of individual investors, especially those seeking the best brokerage account opening offers and practical platform usage tutorials, by providing timely, specific, and highly reliable information, ensuring they can make the smartest and most efficient decisions in the ever-changing global financial markets.Theinvestmedia.com's core team comprises seasoned investment bankers, securities firm management, and Certified Public Accountants (CPAs), boasting over eight years of hands-on financial investment experience. The team deeply understands the critical impact of financial information's professionalism and timeliness on investment decisions. This in-depth update focusing on brokerage account opening tutorials and exclusive offers is a testament to the team's commitment to transforming rich experience into tangible user value.Exclusive Brokerage Account Opening Offers: Real-World Testing and In-Depth Tutorial AnalysisIn response to the market's strong interest in brokerage account opening offers, Theinvestmedia.com not only provides a detailed list of all publicly available offers but also exclusively reveals account opening promotions launched in collaboration with various licensed financial brokerage partners (for details, please refer to Theinvestmedia.com's official website). These offers are not only highly attractive, but the team also provides an in-depth analysis in the tutorials, covering the application process, terms and conditions, and how to maximize the value of these account opening offers. This aims to help users clearly understand the benefits and avoid any potential confusion. The team's goal is to ensure users receive the most transparent and comprehensive information when choosing to open accounts with top-tier brokers (e.g., IBKR account opening offers, Futu, Tiger, OSL, etc.).Practical Guides: From Illustrated Brokerage Account Opening Procedures to Advanced Platform Usage Tutorials and StrategiesBeyond the brokerage account opening offers comparison, another major highlight of this update is a series of brokerage account opening and platform usage practical tutorials, thoroughly tested and verified by the team. These in-depth tutorials cover:Most Detailed Illustrated Account Opening Procedures and Techniques: Providing illustrated steps and tips for common account opening queries and operational challenges (e.g., illustrated IBKR account opening procedures).In-Depth Navigation of Different Securities Platform Functions: Introducing the trading interfaces and frequently used features for diverse investment products (e.g., US stocks, Hong Kong stocks, Japanese stocks, forex, bonds, ETFs, etc.) available on these platforms.Foreign Exchange Rate Comparisons : Offering practical advice on foreign exchange rate comparisons for USD to HKD, Yen to HKD, GBP to HKD, EUR to HKD, CAD to HKD, AUD to HKD, RMB to HKD, SGD to HKD, and other foreign currencies, as well as guidance on deposits and withdrawals in various currencies.Specific Trading Tools and Strategy Application: Sharing how the senior team leverages brokerage platforms for effective risk management and strategy execution for wealth management purpose.Every guide undergoes meticulous data collection from multiple sources, citing only authoritative data from official reports of licensed brokers and multiple account opening tests. Before publication, all content undergoes rigorous multi-team internal verification and professional review by senior compliance advisors, ensuring the authority and 100% accuracy of the information.Building Trust with a Customer-Centric Approach: User Feedback and Customer Service SupportTheinvestmedia.com is committed to being user-centric, with its trustworthiness built on transparency and prompt responsiveness. The platform has a growing number of email subscribers, whose active engagement and positive feedback widely confirm the practical value of the website's content. Theinvestmedia.com also maintains a professional customer service team, accessible via the website or email (hello@theinvestmedia.com), providing personalized assistance. This ensures that users with any questions regarding brokerage account opening offers, platform usage guides, or other tutorial-related information can receive immediate and professional support during business hours.The platform's founding team stated: "We firmly believe that truly valuable financial information must be practical, timely, and verifiable. This exclusive update on brokerage account opening offers and practical tutorials is our latest achievement in upholding this philosophy. We don't just provide 'fish'; we strive to teach 'fishing,' empowering every investor to confidently navigate the global financial markets."Theinvestmedia.com sincerely invites all readers interested in brokerage account opening offers, securities platform operations, and professional investment knowledge to visit Theinvestmedia.com immediately. Explore these exclusive resources, forged from the experience of financial experts, and embark on your journey of confident investment learning.About Theinvestmedia.comTheinvestmedia.com is an online media platform dedicated to providing individual investors with brokerage account opening offer comparisons and professional investment education. It is operated by an expert team with over eight years of hands-on financial investment experience. The website's content covers diverse investment topics, including US stocks, Hong Kong stocks, Japanese stocks, forex, bonds, and ETFs, with a particular focus on account opening offer comparisons, account opening tutorials, and stock account operations (e.g., IB account opening offers), offering in-depth analysis and explanations. Theinvestmedia.com aims to simplify complex financial concepts, helping investors build a solid foundation of investment knowledge and make informed financial decisions. All content is for actual experience sharing and public educational purposes; the platform does not provide any investment advice.Media & Reader Inquiries:Theinvestmedia.com Public Relations DepartmentEmail: hello@theinvestmedia.comWebsite: https://theinvestmedia.comFacebook: https://www.facebook.com/theinvestmediaX.com: https://x.com/theinvestmediaSOURCE: Theinvestmedia Copyright 2025 ACN Newswire via SeaPRwire.com.

Starter Deck 03 ‘Ω to the Future’ marks the highly anticipated debut of Ultraman Omega in card form, featuring exclusive cards and brand new strategies that bring the latest TV series to life and allowing fans to experience the title hero’s journey.Booster Pack 04 ‘Gleam of Eternal Hope’ introduces powerful new versions of iconic Ultra Heroes including Ultraman Dyna, Z, and Trigger. These upgraded cards unlock expanded tactical possibilities, reshaping the game and delivering fresh competitive angles for seasoned players.With the release of both new sets as well as the return of fan-favourite ExP (Extra Parallel) rarity cards, and momentum building toward the Ultra League World Championship 2026, the Ultraman Card Game is poised to grow its global fanbase and strengthen its presence within the trading card game community.KUALA LUMPUR, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Tsuburaya Productions unveils today the latest additions to the ever-popular Ultraman Card Game - Starter Deck 03 ‘Ω to the Future’ and Booster Pack 04 ‘Gleam of Eternal Hope’, launching globally on Friday, 25 July 2025 and Friday, 1 August 2025 respectively. These upcoming game sets build on the momentum of the newly launched Ultraman Omega television series, as well as beloved characters such as Ultraman Arc, whilst introducing brand-new gameplay mechanics, evolution strategies and dynamic synergies centred around these iconic Ultra Heroes. Ultraman Omega Makes His First-Ever Card Game AppearanceA highlight of the new Starter Deck 03 ‘Ω to the Future’ is the much-anticipated debut of Ultraman Omega in card form. This new deck draws inspiration from the ongoing Ultraman Omega television series, which premiered in Japan earlier this month.Reflecting the show’s narrative, the deck features exclusive cards from the Ultraman Omega series, including the titular Ultraman Omega, Meteokaiju, and fan-favourite Giants of Light such as Ultraman Arc. These new cards introduce fresh gameplay mechanics that reward strategic thinking and foresight, from granting power boosts when fielding characters of the same type to enabling tactical card rotations that encourage smarter deck management. With these new mechanics and play styles, players can look forward to reliving key story moments and experiencing Ultraman Omega’s growth firsthand.As an added early-release bonus, players will also be able to receive a bonus pack of Booster Pack 04 ‘Gleam of Eternal Hope’ for every purchase of Starter Deck 03 ‘Ω to the Future’, offering fans an early taste of the upcoming expansion and even more ways to power up their decks.Fan-Favourite Heroes Return with Upgraded PowersBooster Pack 04 ‘Gleam of Eternal Hope’ continues to expand the strategic possibilities of the game, featuring powerful upgraded cards for popular Ultra Heroes including Ultraman Dyna, Ultraman Z, and Ultraman Trigger.These upgrades introduce new abilities that not only refresh existing decks but also deepen tactical options across competitive formats. With a more extensive card pool, players can look forward to more creative deckbuilding strategies that are sure to influence the current approach to gameplay.Collectors Rejoice: ExP (Extra Parallel) Cards Make a ReturnBack by popular demand, the ExP (Extra Parallel) rarity cards - first introduced in Booster Pack 02 ‘Vortex of Crimson and Azure’ - make a dazzling return in ‘Gleam of Eternal Hope’.These collector-favourite cards are known for their exclusive full-art illustrations, premium foil finish, and elegant gold framing. Scheduled to be revealed on Friday, 1 August 2025, ‘Gleam of Eternal Hope’ will see the addition of two brand-new types of ExP card, offering high visual appeal and collectability for long-time fans and new enthusiasts alike.Exclusive Box Topper: Alien Baltan The Space NinjaAdding to the excitement, each 24-pack box of ‘Gleam of Eternal Hope’ will include a special box topper card featuring Alien Baltan, one of the most iconic villains in Ultraman history.This unique card mirrors Baltan’s illusory powers, allowing an unlimited number of copies to be included in a single deck - a rare and rule-breaking mechanic. The artwork captures the classic scene of Baltan duplicating itself and unleashing its signature red freezing ray, leveraging nostalgia for long-term fans.Fans in Malaysia can look forward to purchasing the English-language Starter Deck 03 ‘Ω to the Future’ at MYR 46.00 and Booster Pack 04 ‘Gleam of Eternal Hope’ in either individual packs at MYR 18.00 or as a 24-pack box at MYR 432.00 at authorised hobby stores, major retailers, and online platforms.These releases are poised to equip both new and veteran Ultra Leaguers with competitive decks ahead of major events, including the upcoming inaugural Ultra League World Championship 2026, set to take place on 9 and 10 May 2026 in Tokyo, Japan. This prestigious tournament will see players from around the world battling through regional qualifiers for a shot at the title of world’s best Ultra Leaguer, with exclusive cards and gameplay accessories up for grabs. For more information on the Ultraman Card Game, please refer to https://ultraman-cardgame.com/page/my/top.About Tsuburaya ProductionsTsuburaya Productions is a global entertainment company providing content, products and services full of creativity and innovation. Since the airing of Ultra Q and Ultraman in 1966, the company has continued to create characters and stories that are loved by fans worldwide.TSUBURAYA PRODUCTIONS Official Global Site: https://tsuburaya-prod.com/Ultraman Card Game Official Website: https://ultraman-cardgame.com/About Ultraman Card GameThe Ultraman Card Game is a dynamic trading card game developed by Tsuburaya Productions, bringing the iconic Ultraman universe to life through strategic gameplay and collectible cards. Designed for fans of all ages, the game features high-quality artwork showcasing Ultraman's heroes, kaiju, and special moves, offering both engaging play and collectibility. With simultaneous releases in multiple languages across various regions, the Ultraman Card Game invites players around the world to explore the rich legacy of Ultraman, engage in epic battles, and grow their collections. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that (Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC.The Approved Product is a multi-dose eye drop formulation containing 3% diquafosol sodium (5ml:150mg), indicated for the treatment of dry eye syndromes such as conjunctival epithelium injury and tear abnormalities. The active pharmaceutical ingredient, diquafosol sodium, is a P2Y2 receptor agonist that acts on conjunctival tissues to promote the secretion of tears containing water and secretory mucins. It may also promote the expression of membrane-bound mucins on corneal epithelium. Boosting the lipid content in tears, it should quantitatively and qualitatively improve tear abnormalities and demonstrate efficacy in bringing the ocular surface condition closer to normal, and improve symptoms of dry eye and corneal epithelial damage.The Approved Product, together with the previously approved preservative-free unit-dose Diquafosol Sodium Eye Drops collectively, collectively provide more high-quality treatment options for patients in the PRC. The approval will further enrich the Group’s ophthalmic product portfolio and strengthen its market position in ophthalmology segment.About Essex (Stock Code:1061.HK)Essex is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,000 hospitals, supported by the Company’s 44 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, Essex maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the “Sellers”), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue.Everest Medicines, together with its controlling shareholder CBC Group and the placing agents, entered into a placing and subscription agreement for the sale of 22,561,000 shares at a purchase price of HK$69.70 per share, representing:- a discount of approximately 10.12% to the closing price of HK$77.55 per share on July 24, 2025.- a discount of approximately 4.98% to the average closing price of HK$73.35 per Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to and including the Last Trading Date.- a premium of 16.15% to the volume weighted average price of HK$60.01 per Share as quoted on the Stock Exchange for the thirty consecutive trading days immediately prior to the Last Trading Date and including the Last Trading Date.The gross proceeds from the Placing and Subscription are expected to be approximately HK$1,572.50 million, and the net proceeds (after deducting all related expenses, including commission and levies) will be approximately HK$1,553.39 million.Everest Medicines intends to use approximately 50% of the net proceeds (approximately HK$776.69 million) to support global research and development of pipeline products, approximately 40% (approximately HK$621.36 million) to commercialization efforts including the launch of new products, and 10% (approximately HK$155.34 million) to working capital and general corporate purposes.“This placement was well-received by several leading international long-only funds and was significantly oversubscribed, reflecting strong capital market confidence in Everest’s commercial execution capabilities and innovative R&D strengths,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “It also underscores investors’ endorsement of our long-term strategic vision. We will use the proceeds to accelerate the development of innovative pipelines and our proprietary AI+mRNA platform, while advancing the commercialization of our existing portfolio. With a strengthened capital base, we are poised to drive both commercialization and innovation, delivering greater value to patients and shareholders.”Everest has built an industry-leading, fully integrated, and localized AI+mRNA platform, enabling the development of multiple oncology and autoimmune disease programs, including EVM14, an off-the-shelf therapeutic mRNA cancer vaccine; EVM16, a personalized mRNA cancer vaccine; and an in vivo CAR-T program aimed at building a differentiated portfolio of precision immunotherapies.- The first patient has been dosed with Everest’s internally developed personalized mRNA cancer vaccine (PCV) EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT). Early results showed strong immunogenicity and specific T-cell responses even at a low starting dose in advanced cancer patients.- The Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine, has been accepted by both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), making it Everest's first mRNA cancer therapeutic vaccine to achieve dual IND submissions in both China and the United States. The first clinical batch of EVM14 was successfully released from Everest’s Jiashan manufacturing site on June 9, and is anticipated to be delivered to U.S. clinical centers by mid-August. This batch will support the clinical trials of EVM14 in both China and the United States (US).- Everest’s in vivo CAR-T program is founded upon its proprietary targeted LNP (tLNP) delivery system and has shown promising results in both humanized mouse models and non-human primates. It offers key advantages including off-the-shelf availability, lymphodepletion-free administration, and dose controllability.EVER001, a next-generation covalent reversible BTK inhibitor with global rights, is advancing through global multi-center clinical studies for glomerular diseases such as primary membranous nephropathy (pMN). Positive results from its Phase 1b/2a clinical trial demonstrated rapid onset, durable response, good tolerability, and oral convenience, offering strong potential to address unmet needs in renal disease treatment worldwide.NEFECON®, the first and only etiological treatment for IgA nephropathy (IgAN) full approved in China, the U.S., and Europe, continues to gain strong commercial traction in China following its inclusion in the National Reimbursement Drug List (NRDL), benefiting over 20,000 patients to date. Everest is also accelerating the development of its proprietary diagnostic test for Gd-IgA1 to build an integrated disease management ecosystem encompassing diagnosis, treatment, and long-term care.The New Drug Application (NDA) for Etrasimod (VELSIPITY®) has been accepted in Mainland China, with approval anticipated between late 2025 and early 2026. The NDA has also been accepted in South Korea. VELSIPITY® has been commercially launched in Macao SAR, Singapore and Hong Kong SAR in 2024. As Everest’s third commercialized product, VELSIPITY® has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. In March 2025, Everest has launched the construction project at its Jiashan manufacturing site to support the local production for VELSIPITY®.Everest Medicines is accelerating the strategic advancement of its core pipeline and AI+mRNA technology platforms to further solidify its position as a leading innovative biopharmaceutical company in Asia.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2025 ACN Newswire via SeaPRwire.com.

- The implementation of streamlined approval procedures for Hong Kong- and Macao-registered proprietary Chinese medicines (“pCms”) by mainland China presents significant opportunities for Hong Kong companies to expand into the Greater Bay Area and other mainland market.- A unified and comprehensive registration system strengthens the quality control of Hong Kong's pCms, reinforcing confidence among other regulatory bodies and stakeholders.- Hong Kong's first Chinese medicine hospital will gradually commence operations by year end. This will help promote the popularity of Chinese medicine and pCms.HONG KONG, July 24, 2025 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Trade Development Council (“HKTDC”) today released a report, "Challenges and Opportunities in Hong Kong's Proprietary Chinese Medicine Industry," that analyses the sector’s development, challenges, and export potential of Hong Kong’s pCm sector. With the completion of the transitional registration process for pCms in June this year, all pCms sold in Hong Kong now hold formal registration, marking a new era in the regulatory regime. The Chinese Medicine Hospital of Hong Kong is set to begin operations by late 2025 further popularising pCms. Additionally, mainland China has streamlined approval procedures for Hong Kong-registered traditional pCms, creating easier access to the mainland market.Hong Kong’s pCms enjoy a strong reputation, with streamlined registration procedures facilitating expansion into the Mainland marketHong Kong currently has approximately 2,000 companies involved in pCms and Chinese herbal medicine-related businesses, including import/export trade, manufacturing, wholesale and retail. Among these, some 264 enterprises are listed as local pCm manufacturers. The majority of pCms produced in Hong Kong are geared toward the consumer market. In 2024, Hong Kong’s pCm exports totaled HK$2.88 billion with 93% locally produced, setting the industry apart from re-export-driven sectors. Mainland China remains the largest export market, accounting for over 70% of exports, followed by Macao (20%), and ASEAN (6%).Wing Chu, Principal Economist (Greater China) of the HKTDC, stated: "Many Hong Kong proprietary Chinese medicines companies are eager to expand exports especially to the mainland market although pCm imports in mainland China are relatively small, with different pCms registration system and technical standards from those of Hong Kong. Notably, Hong Kong’s pCms are highly regarded in Southern China and overseas Chinese communities, and streamlined approval procedures in mainland China for traditional pCms of Hong Kong and Macao offer significant opportunities for Hong Kong businesses to expand into the Greater Bay Area and other mainland markets. Additionally, the rise of online shopping enables companies to leverage cross-border e-commerce platforms to access mainland and overseas markets, provided they comply with the corresponding regulatory requirements.”Comprehensive registration system drives standardisation of Chinese medicineThe report indicates that, in recent years, the HKSAR Government has actively promoted the development of Chinese medicine. Key initiatives include the establishment of the Chinese Medicine Council of Hong Kong to oversee the registration and management of pCms, and continuous support for Chinese medicine services in areas such as education, medical treatment, and scientific research. These efforts have enabled Hong Kong to cultivate professional Chinese medicine talent and promote the modernisation of Chinese medicine. Earlier this month, some 345 Hong Kong enterprises, including traders, registered a total of 8,244 pCms.The report states that a unified and comprehensive registration system enhances the quality control of Hong Kong's pCms, further increasing the confidence of other regulatory bodies and stakeholders in these products. Hong Kong's first Chinese medicine hospital is set to open in late 2025, providing comprehensive diagnostic and treatment services with Chinese medicine, which will drive the popularisation of Chinese medicine and pCms.In addition, Hong Kong pCm companies and local universities are committed to developing new pCms to further expand the market. Recently, the Centre for Chinese Herbal Medicine Drug Development at Hong Kong Baptist University (HKBU), funded by the Innovation and Technology Commission of HKSAR Government under the InnoHK Research Clusters, developed a novel drug, CDD-2101, for the treatment of chronic constipation. The innovation is based on previous pilot clinical studies and basic research on the traditional Chinese herbal formulation "MaZiRenWan”. For the first time, it has received authorisation for clinical research in the United States.Prof. BIAN Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development and Associate Vice-President (Clinical Chinese Medicine) at HKBU, said: "Our goal is to collect sufficient safety and efficacy data to obtain FDA approval for CDD-2101 as a marketable new drug and successfully launch it in the United States. This represents not only a major breakthrough in the research and development of Chinese medicine in Hong Kong but also an important step in driving the standardisation and internationalisation of Chinese medicine.”Mainland market surpasses RMB450 billionMainland China, the world's largest pCm market valued at RMB450 billion, streamlined registration and approval procedures in 2021 for traditional pCms for external use being sold in Hong Kong and Macao. In January 2025, the National Medical Products Administration further simplified the approval process for traditional pCms for oral use, provided they have been in use in Hong Kong for more than 15 years and whose production processes comply with Good Manufacturing Practice (GMP) requirements. Relevant application materials and technical requirements were also released in April this year. The report notes that the implementation of the streamlined registration procedures opens a more convenient channel for Hong Kong companies to expand into the Greater Bay Area and other mainland markets.The recognition and acceptance of pCms differ across overseas regions. In many international markets, pCms are categorised and regulated as herbal medicines, health foods or dietary supplements. However, many Southeast Asian countries have specific, similar legal requirements for pCms, providing a clear pathway to enter these markets.The rapid growth of global e-commerce has created new sales channels for Hong Kong’s pCms through cross-border e-retail. For the mainland market, the report points out that certain pCms for external use, such as Chinese medicinal wines and cooling oils, have been incorporated in the Cross-border E-commerce Retail Import Commodity List, allowing relevant products to be sold to mainland China through cross-border e-commerce channels.In overseas markets, the e-commerce retail sector in ASEAN is experiencing significant growth, fueled by robust demand for herbal and health-related products in local markets. By adhering to local regulations, Hong Kong pCm enterprises can capitalise on additional business opportunities through online channels.Annual Chinese Medicine Conference to Share Latest Research FindingsTo foster the development of the Chinese medicine industry, the International Conference of the Modernization of Chinese Medicine & Health Products will be held at the Hong Kong Convention and Exhibition Centre from 15 to 16 August 2025. The conference is jointly organised by the Modernized Chinese Medicine International Association, the HKTDC and 10 scientific research institutions. During the event, 21 scholars and experts from medical schools, research institutions, pharmaceutical companies and organisations from mainland China, Hong Kong, Malaysia and Thailand will discuss the latest research progress in the prevention and treatment of tumors, inflammation, and cardiovascular and cerebrovascular diseases using traditional medicine. They will also present a number of related clinical research results and share successful cases. For more details, please visit: https://www.hktdc.com/event/icmcm/en.Report and photo download: https://bit.ly/45kCaXuThe HKTDC today released its research report, "Challenges and Opportunities in Hong Kong's Proprietary Chinese Medicine Industry." Pictured from left are Wing Chu, Principal Economist (Greater China Research Team) at the HKTDC, and Prof. Bian Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development at Hong Kong Baptist UniversityWing Chu, Principal Economist (Greater China Research Team) at the HKTDC, pointed out that mainland China has streamlined the approval procedures for eligible traditional proprietary Chinese medicines from Hong Kong and Macao, providing more opportunities for Hong Kong businesses to expand into the Greater Bay Area and mainland marketsProf. Bian Zhaoxiang, Director of the Centre for Chinese Herbal Medicine Drug Development at HKBU, stated that the university’s earlier development of a novel drug for chronic constipation is based on an ancient Chinese herbal formulation and was authorised for clinical research in the United States for the first time. This marked an important step in driving the standardisation and internationalisation of Chinese medicineMedia EnquiriesOgilvy Public RelationsChole ChanTel: (852) 6809 6633Email: chloe.chan@ogilvy.comLeanne PokTel: (852) 9379 9694Email: leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley SoTel: (852) 2584 4049Email: stanley.hp.so@hktdc.orgSerena CheungTel: (852) 2584 4272Email: serena.hm.cheung@hktdc.orgClayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgMedia Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.